A novel dendritic cell-based vaccination protocol to stimulate immunosurveillance of aggressive cancers

Annunziata Nigro, Barbara Montico, Vincenzo Casolaro, Jessica Dal Col

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

A major challenge in the development of a successful tumor vaccination is to break immune tolerance and to sensitize efficiently the immune system toward relevant tumor antigens, thus enabling T-cell-mediated antitumor responses in vivo. Dendritic cell (DC)-based immunotherapy shows the advantage to induce an adaptive immune response against the tumor, with the potential to generate a long-lasting immunological memory able to prevent further relapses and hopefully metastasis. Recently different preclinical studies highlighted the golden opportunity to exploit the features of immunogenic cell death (ICD) to generate ex vivo a highly immunogenic tumor cell lysate as potent antigen formulation for improved DC-based vaccine against aggressive cancers. This chapter focuses on the methods to obtain tumor lysates from cells undergoing ICD to be used for DC pulsing and to test the functionality of the generated DCs for antitumor vaccine development.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages317-333
Number of pages17
DOIs
Publication statusPublished - Jan 1 2019

Publication series

NameMethods in Molecular Biology
Volume1884
ISSN (Print)1064-3745

Fingerprint

Immunologic Monitoring
Dendritic Cells
Vaccination
Neoplasms
Cell Death
Vaccines
Immunologic Memory
Immune Tolerance
Adaptive Immunity
Neoplasm Antigens
Immunotherapy
Immune System
Neoplasm Metastasis
T-Lymphocytes
Antigens
Recurrence

Keywords

  • Active immunotherapy
  • Anticancer vaccine
  • Dendritic cells
  • Immunogenic cell death

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Nigro, A., Montico, B., Casolaro, V., & Dal Col, J. (2019). A novel dendritic cell-based vaccination protocol to stimulate immunosurveillance of aggressive cancers. In Methods in Molecular Biology (pp. 317-333). (Methods in Molecular Biology; Vol. 1884). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-8885-3_22

A novel dendritic cell-based vaccination protocol to stimulate immunosurveillance of aggressive cancers. / Nigro, Annunziata; Montico, Barbara; Casolaro, Vincenzo; Dal Col, Jessica.

Methods in Molecular Biology. Humana Press Inc., 2019. p. 317-333 (Methods in Molecular Biology; Vol. 1884).

Research output: Chapter in Book/Report/Conference proceedingChapter

Nigro, A, Montico, B, Casolaro, V & Dal Col, J 2019, A novel dendritic cell-based vaccination protocol to stimulate immunosurveillance of aggressive cancers. in Methods in Molecular Biology. Methods in Molecular Biology, vol. 1884, Humana Press Inc., pp. 317-333. https://doi.org/10.1007/978-1-4939-8885-3_22
Nigro A, Montico B, Casolaro V, Dal Col J. A novel dendritic cell-based vaccination protocol to stimulate immunosurveillance of aggressive cancers. In Methods in Molecular Biology. Humana Press Inc. 2019. p. 317-333. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-8885-3_22
Nigro, Annunziata ; Montico, Barbara ; Casolaro, Vincenzo ; Dal Col, Jessica. / A novel dendritic cell-based vaccination protocol to stimulate immunosurveillance of aggressive cancers. Methods in Molecular Biology. Humana Press Inc., 2019. pp. 317-333 (Methods in Molecular Biology).
@inbook{b1c83bc129bc46c99c8842ca9a6d0c61,
title = "A novel dendritic cell-based vaccination protocol to stimulate immunosurveillance of aggressive cancers",
abstract = "A major challenge in the development of a successful tumor vaccination is to break immune tolerance and to sensitize efficiently the immune system toward relevant tumor antigens, thus enabling T-cell-mediated antitumor responses in vivo. Dendritic cell (DC)-based immunotherapy shows the advantage to induce an adaptive immune response against the tumor, with the potential to generate a long-lasting immunological memory able to prevent further relapses and hopefully metastasis. Recently different preclinical studies highlighted the golden opportunity to exploit the features of immunogenic cell death (ICD) to generate ex vivo a highly immunogenic tumor cell lysate as potent antigen formulation for improved DC-based vaccine against aggressive cancers. This chapter focuses on the methods to obtain tumor lysates from cells undergoing ICD to be used for DC pulsing and to test the functionality of the generated DCs for antitumor vaccine development.",
keywords = "Active immunotherapy, Anticancer vaccine, Dendritic cells, Immunogenic cell death",
author = "Annunziata Nigro and Barbara Montico and Vincenzo Casolaro and {Dal Col}, Jessica",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-8885-3_22",
language = "English",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "317--333",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - A novel dendritic cell-based vaccination protocol to stimulate immunosurveillance of aggressive cancers

AU - Nigro, Annunziata

AU - Montico, Barbara

AU - Casolaro, Vincenzo

AU - Dal Col, Jessica

PY - 2019/1/1

Y1 - 2019/1/1

N2 - A major challenge in the development of a successful tumor vaccination is to break immune tolerance and to sensitize efficiently the immune system toward relevant tumor antigens, thus enabling T-cell-mediated antitumor responses in vivo. Dendritic cell (DC)-based immunotherapy shows the advantage to induce an adaptive immune response against the tumor, with the potential to generate a long-lasting immunological memory able to prevent further relapses and hopefully metastasis. Recently different preclinical studies highlighted the golden opportunity to exploit the features of immunogenic cell death (ICD) to generate ex vivo a highly immunogenic tumor cell lysate as potent antigen formulation for improved DC-based vaccine against aggressive cancers. This chapter focuses on the methods to obtain tumor lysates from cells undergoing ICD to be used for DC pulsing and to test the functionality of the generated DCs for antitumor vaccine development.

AB - A major challenge in the development of a successful tumor vaccination is to break immune tolerance and to sensitize efficiently the immune system toward relevant tumor antigens, thus enabling T-cell-mediated antitumor responses in vivo. Dendritic cell (DC)-based immunotherapy shows the advantage to induce an adaptive immune response against the tumor, with the potential to generate a long-lasting immunological memory able to prevent further relapses and hopefully metastasis. Recently different preclinical studies highlighted the golden opportunity to exploit the features of immunogenic cell death (ICD) to generate ex vivo a highly immunogenic tumor cell lysate as potent antigen formulation for improved DC-based vaccine against aggressive cancers. This chapter focuses on the methods to obtain tumor lysates from cells undergoing ICD to be used for DC pulsing and to test the functionality of the generated DCs for antitumor vaccine development.

KW - Active immunotherapy

KW - Anticancer vaccine

KW - Dendritic cells

KW - Immunogenic cell death

UR - http://www.scopus.com/inward/record.url?scp=85056920054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056920054&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-8885-3_22

DO - 10.1007/978-1-4939-8885-3_22

M3 - Chapter

T3 - Methods in Molecular Biology

SP - 317

EP - 333

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -